You are here

Novo Nordisk

Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump

CNBC

Wed, 02/5/25 - 10:42 pm

Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects

Fierce Biotech

Wed, 02/5/25 - 11:21 am

clinical trials

diabetic kidney disease

Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema

Yahoo/Reuters

Tue, 02/4/25 - 06:11 pm

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

Motley Fool

Mon, 02/3/25 - 11:55 am

Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say

Forbes

Fri, 01/31/25 - 10:59 am

Novo Nordisk commences fresh trials for CagriSema

Devdiscourse

Thu, 01/30/25 - 11:33 am

clinical trials

FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD

Healio

Tue, 01/28/25 - 09:42 pm

Veru's drug conserves muscle mass for older patients taking Novo's Wegovy in phase 2 trial

Fierce Biotech

Tue, 01/28/25 - 10:17 am

Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35

MSN/Reuters

Mon, 01/27/25 - 10:51 pm

Novo Nordisk links next-gen obesity drug to 22% weight loss at Week 36, sending stock up 11%

Fierce Biotech

Fri, 01/24/25 - 11:47 am

clinical trials

Novo Nordisk gets BACH1, inking IMMvention deal to orchestrate attack on sickle cell disease

Fierce Biotech

Wed, 01/22/25 - 11:55 am

sickle cell disease

IMMvention Therapeutix

Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's

Fierce Pharma

Tue, 01/21/25 - 07:13 pm

Alzheimer's disease

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

Fierce Pharma

Fri, 01/17/25 - 11:34 am

clinical trials

Ozempic tops new Medicare price negotiation list

Pharmaphorum

Fri, 01/17/25 - 11:10 am

Inflation Reduction Act

5 questions facing pharma in 2025

BioPharma Dive

Fri, 01/10/25 - 11:47 am

Launches from Novo, Lilly top Clarivate's annual 'Drugs to Watch' list

Fierce Pharma

Wed, 01/8/25 - 11:20 pm

Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes

Fierce Biotech

Wed, 01/8/25 - 11:23 am

artificial intelligence

Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data

Fierce Biotech

Tue, 01/7/25 - 11:37 am

metabolic disorders

Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row

Fierce Pharma

Sun, 01/5/25 - 09:40 pm

Use of diabetes and anti-obesity drugs surges nationwide

Axios

Fri, 01/3/25 - 10:07 am

Pages